Orphan status joins Fast Track for Noema's basimglurant: what it does and doesn't mean
FDA's orphan designation for Noema's oral mGluR5 modulator in trigeminal neuralgia adds incentives, not evidence. A busy week of FDA decisions shows where the real regulatory hurdles sit.
What happened
On 16 November 2026, Noema Pharma announced that the US FDA granted orphan drug designation to basimglurant for trigeminal neuralgia, a rare and painful neuropathic condition. Basimglurant is an oral mGluR5 modulator. It already holds FDA Fast Track status, so the program now carries two of the agency's best-known development-support labels.
The records do not say which development stage the program is in, what data support the designation request, or when Noema expects to file a marketing application. Those details matter for any outlook and are not yet known from the announcement.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- FDA grants orphan drug designation to Noema's basimglurant for trigeminal neuralgia Noema Pharma AG · Mon 16 Nov 2026
- FDA approves Novartis' Cosentyx 150 mg for polymyalgia rheumatica Novartis Pharma AG · Tue 17 Nov 2026
- FDA approves Roche's Wilserdly with everolimus for ESR1-mutated advanced breast cancer Roche · Mon 16 Nov 2026
- FDA approves Roche's oral SERD Wilserdly with everolimus for ESR1-mutated breast cancer F. Hoffmann-La Roche Ltd · Mon 16 Nov 2026
- iMDx Pauses FDA De Novo Review of GraftAssureDx Kidney Rejection Test, Plans January Response Insight Molecular Diagnostics Inc. · Mon 16 Nov 2026
- Cumberland to file ifetroban NDA for Duchenne cardiomyopathy under FDA rolling submission Cumberland Pharmaceuticals Inc · Mon 16 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Tablo power cord overheating alert shows how a simple instruction change becomes a PV control
FDA's early alert on Outset Medical's Tablo cords is a reminder that use-instruction updates depend on reporting, user follow-through and a clear view of what is still unknown.
Lantern Pharma's first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise
Lantern Pharma reported trial milestones for LP-184 and LP-300 in the same release as a CEO resignation and a roughly $4.0M offering, a mix sponsors and CROs should read carefully.
EEA Decision 191/2026 extends six EU feed additive acts to EEA EFTA markets, minus Liechtenstein
The EEA Joint Committee has added six feed additive acts, including a monensin sodium renewal and a Duddingtonia flagrans approval, to Annex I. Market access teams should read it as a lesson in how EU rules reach EEA markets.